Literature DB >> 20824707

Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients.

Cecilia Magnusson1, Jian Liu, Roy Ehrnström, Jonas Manjer, Karin Jirström, Tommy Andersson, Anita Sjölander.   

Abstract

The fact that breast cancer patients with local or distal dissemination exhibit decreased survival, promotes a search for novel mechanisms to suppress such tumor progression. Here, we have determined the expression of proinflammatory cysteinyl leukotriene receptors (CysLTRs) in breast tumor tissue and their signaling effect on breast cancer cell functions related to tumor progression. Patients with breast tumors characterized by high CysLT(1)R and low CysLT(2)R expression levels exhibited increased risk of cancer-induced death in univariate analysis for both the total patient group (hazard ratio [HR] = 2.88, 95% confidence interval [CI] = 1.11-7.41), as well as patients with large (>20 mm) tumors (HR = 5.08, 95% CI = 1.39-18.5). Multivariate analysis revealed that patients with large tumors exhibiting high CysLT(1)R and low CysLT(2)R expression levels had a significantly reduced survival, also when adjusted for established prognostic parameters (HR = 7.51, 95% CI = 1.83-30.8). In patients with large (>20 mm) tumors, elevated CysLT(2)R expression predicted an improved 5-year survival (log-rank test p = 0.04). Surprisingly, for longer time periods, this prognostic value was lost. This disappearance coincided with the termination of hormonal treatment. Tamoxifen preserved and even induced transcription of CysLT(2)R, but not CysLT(1)R, in estrogene receptor-positive MCF-7 breast cancer cells. This elevated CysLT(2)R expression decreased, even below the level of untreated cells, when tamoxifen was withdrawn. CysLT(2)R signaling reduced MCF-7 cell migration, but had no effect on either proliferation or apoptosis. Our data indicate that low CysLT(1)R together with high CysLT(2)R expression levels might be useful parameters in prognostication and treatment stratification of breast cancer patients.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824707     DOI: 10.1002/ijc.25648

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

Review 2.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

3.  A new correlation clustering method for cancer mutation analysis.

Authors:  Jack P Hou; Amin Emad; Gregory J Puleo; Jian Ma; Olgica Milenkovic
Journal:  Bioinformatics       Date:  2016-08-18       Impact factor: 6.937

Review 4.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

5.  Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism.

Authors:  Cecilia Magnusson; Astrid M Bengtsson; Minghui Liu; Jian Liu; Yvonne Ceder; Roy Ehrnström; Anita Sjölander
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

6.  5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation.

Authors:  Shigeyuki Magi; Yasushi Takemoto; Hiroki Kobayashi; Masato Kasamatsu; Takahiro Akita; Ayako Tanaka; Kei Takano; Etsu Tashiro; Yasuhiro Igarashi; Masaya Imoto
Journal:  Cancer Sci       Date:  2014-01-28       Impact factor: 6.716

7.  Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients.

Authors:  Ming-Ju Tsai; Ping-Hsun Wu; Chau-Chyun Sheu; Ya-Ling Hsu; Wei-An Chang; Jen-Yu Hung; Chih-Jen Yang; Yi-Hsin Yang; Po-Lin Kuo; Ming-Shyan Huang
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

8.  The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.

Authors:  Kishan Bellamkonda; Naveen Kumar Chandrashekar; Janina Osman; Benson Chellakkan Selvanesan; Sayeh Savari; Anita Sjölander
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

9.  CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer.

Authors:  Sayeh Savari; Minghui Liu; Yuan Zhang; Wondossen Sime; Anita Sjölander
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

10.  Upregulation of leukotriene receptors in gastric cancer.

Authors:  Marino Venerito; Doerthe Kuester; Caroline Harms; Daniel Schubert; Thomas Wex; Peter Malfertheiner
Journal:  Cancers (Basel)       Date:  2011-08-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.